Your browser doesn't support javascript.
SARS-CoV-2 B.1.617 emergence and sensitivity to vaccine-elicited antibodies
Petra Mlcochova; Steven A Kemp; Mahesh Shanker Dhar; Guido Papa; Bo Meng; Swapnil Mishra; Charlie Whittaker; Thomas Mellan; Isabella Ferreira; Rawlings Datir; Dami Collier; Sujeet Singh; Rajesh Pandey; Kalaiarasan Ponnusamy; V S Radhakrishnan; Shantanu Sengupta; Jonathan Brown; Robin Marwal; Kalaiarasan Ponnusamy; V.S. Radhakrishnan; Niluka Goonawardne; Adam Abdullahi; Priti Devi; Chand Wattal; Daniela Caputo; Tom Peacock; Neeraj Goel; Raju Vaishya; Oscar Charles; Partha Chattopadhyay; Meenakshi Agarwal; Ambrish Satwik; - INSACOG CONSORTIUM; - NIHR Bioresource Collaboration; Antranik Mavousian; Jonathan Brown; Jie Zhou; Niluka Goonawardne; Joo Hyeon Lee; Jessica Bassi; Chiara Silacci-Fegni; Christian Saliba; Dora Pinto; Takashi Irie; Isao Yoshida; William L Hamilton; Kei Sato; Leo James; Davide Corti; Luca Piccoli; Samir Bhatt; Seth Flaxman; Wendy Barlcay; Partha Rakshit; Anurag Agrawal; Ravindra K Gupta.
  • Petra Mlcochova; University of Cambridge
  • Steven A Kemp; UCL
  • Mahesh Shanker Dhar; National Centre for Disease Control, Delhi, India
  • Guido Papa; MRC LMB
  • Bo Meng; University of Cambridge
  • Swapnil Mishra; Imperial College
  • Charlie Whittaker; Imperial
  • Thomas Mellan; Imperial
  • Isabella Ferreira; Cambridge
  • Rawlings Datir; Cambridge University
  • Dami Collier; University of Cambridge
  • Sujeet Singh; National Centre for Disease Control, Delhi, India
  • Rajesh Pandey; CSIR Institute of Genomics and Integrative Biology, Delhi, India
  • Kalaiarasan Ponnusamy; National Centre for Disease Control, Delhi, India
  • V S Radhakrishnan; National Centre for Disease Control, Delhi, India
  • Shantanu Sengupta; CSIR Institute of Genomics and Integrative Biology
  • Jonathan Brown; Imperial
  • Robin Marwal; National Centre for Disease Control
  • Kalaiarasan Ponnusamy; National Centre for Disease Control, Delhi, India
  • V.S. Radhakrishnan; National Centre for Disease Control, Delhi, India
  • Niluka Goonawardne; Imperial
  • Adam Abdullahi; University of Cambridge
  • Priti Devi; CSIR Institute of Genomics and Integrative Biology, Delhi, India
  • Chand Wattal; Ganga Ram Hospital
  • Daniela Caputo; Cambridge NIHR Bioresource
  • Tom Peacock; Imperial
  • Neeraj Goel; Ganga Ram
  • Raju Vaishya; Indraprastha Apollo Hospital, New Delhi
  • Oscar Charles; UCL
  • Partha Chattopadhyay; CSIR Institute of Genomics and Integrative Biology, Delhi, India
  • Meenakshi Agarwal; Northern Railway Central Hospital, New Delhi, India
  • Ambrish Satwik; Sri Ganga Ram Hospital, New Delhi, India
  • - INSACOG CONSORTIUM; -
  • - NIHR Bioresource Collaboration; -
  • Antranik Mavousian; Cambridge Stem Cell Institute
  • Jonathan Brown; Imperial College
  • Jie Zhou; Imperial College
  • Niluka Goonawardne; Imperial College
  • Joo Hyeon Lee; Cambridge Stem Cell Institute
  • Jessica Bassi; Vir
  • Chiara Silacci-Fegni; Vir
  • Christian Saliba; Vir
  • Dora Pinto; Vir
  • Takashi Irie; Institute of Biomedical and Health Sciences, Hiroshima University, Hiroshima 7348551, Japan
  • Isao Yoshida; Tokyo Metropolitan Institute of Public Health, Tokyo 1690073, Japan
  • William L Hamilton; University of Cambridge
  • Kei Sato; University of Tokyo
  • Leo James; MRC LMB
  • Davide Corti; Vir
  • Luca Piccoli; Vir
  • Samir Bhatt; University of Copenhagen
  • Seth Flaxman; Imperial
  • Wendy Barlcay; Imperial
  • Partha Rakshit; National Centre for Disease Control, Delhi, India
  • Anurag Agrawal; CSIR Institute of Genomics and Integrative Biology, Delhi, India
  • Ravindra K Gupta; University of Cambridge
预印本 在 英语 | bioRxiv | ID: ppbiorxiv-443253
ABSTRACT
The SARS-CoV-2 B.1.617.2 (Delta) variant was first identified in the state of Maharashtra in late 2020 and spread throughout India, outcompeting pre-existing lineages including B.1.617.1 (Kappa) and B.1.1.7 (Alpha). In vitro, B.1.617.2 is 6-fold less sensitive to serum neutralising antibodies from recovered individuals, and 8-fold less sensitive to vaccine-elicited antibodies as compared to wild type Wuhan-1 bearing D614G. Serum neutralising titres against B.1.617.2 were lower in ChAdOx-1 versus BNT162b2 vaccinees. B.1.617.2 spike pseudotyped viruses exhibited compromised sensitivity to monoclonal antibodies against the receptor binding domain (RBD) and N-terminal domain (NTD), in particular to the clinically approved bamlavinimab and imdevimab monoclonal antibodies. B.1.617.2 demonstrated higher replication efficiency in both airway organoid and human airway epithelial systems as compared to B.1.1.7, associated with B.1.617.2 spike being in a predominantly cleaved state compared to B.1.1.7. Additionally we observed that B.1.617.2 had higher replication and spike mediated entry as compared to B.1.617.1, potentially explaining B.1.617.2 dominance. In an analysis of over 130 SARS-CoV-2 infected healthcare workers across three centres in India during a period of mixed lineage circulation, we observed substantially reduced ChAdOx-1 vaccine efficacy against B.1.617.2 relative to non-B.1.617.2. Compromised vaccine efficacy against the highly fit and immune evasive B.1.617.2 Delta variant warrants continued infection control measures in the post-vaccination era.
全文: 可用 采集: 预印本 资料库: bioRxiv 类型: 预印本 语言: 英语 年: 2021

相关文档

MEDLINE

...
LILACS

LIS

全文: 可用 采集: 预印本 资料库: bioRxiv 类型: 预印本 语言: 英语 年: 2021
...